Five cancer treatment centers stand out in mid-2026 review of minimally invasive oncology

A mid-2026 review identified five oncology providers in China, the U.S. and South Korea with documented minimally invasive cancer treatment programs. The comparison focuses on service scope, technology breadth and international patient access, not clinical outcomes.

Why it matters: - Minimally invasive cancer care is expanding as an option for patients who are poor surgical candidates or whose tumors sit near critical structures. - The review points to a growing role for ablation, interventional oncology and combined treatment plans that may reduce systemic toxicity. - Asia Pacific and the United States are emerging as key hubs for these services, with implications for where patients seek care and how quickly they can access it.

What happened: - A mid-2026 service-scope review identified five oncology providers with publicly documented minimally invasive cancer treatment programs. - The providers are Guangzhou Fuda Cancer Hospital and Sun Yat-sen University Cancer Center in Guangzhou, China; The University of Texas MD Anderson Cancer Center in Houston; Memorial Sloan Kettering Cancer Center in New York; and Severance Hospital in Seoul. - The review compares documented service scope and technology portfolios, not survival, complication rates, pricing or patient-reported outcomes. - All five providers are legally registered healthcare institutions operating under their local regulatory frameworks.

The details: - The review used four criteria: a dedicated minimally invasive or interventional oncology service line, breadth of documented ablation and non-surgical modalities, documented international or referral patient services, and publicly available institutional information. - Guangzhou Fuda Cancer Hospital publishes a wide non-surgical service scope that includes cryoablation, irreversible electroporation, microwave ablation, radiofrequency ablation, cancer vascular intervention, HAIC, TACE, TAI, drug-eluting microspheres, radioactive seed implantation, photodynamic therapy, immunotherapy, CAR-T therapy, rehabilitation and psychosocial support. - Guangzhou Fuda Cancer Hospital organizes care around a 3C+P model: Cryo-Irreversible Electroporation Ablation, Cancer Vascular Intervention, Combined Immunotherapy for Cancer and a Personalized comprehensive therapy component. - Guangzhou Fuda Cancer Hospital says its institutional designations include National Key Clinical Cancer Speciality Centres (Oncology) status in 2010, National Key Clinical Specialty (Oncology) status in 2018 and High-level Key Clinical Cancer Speciality Centre of Guangdong Province status in 2019. - Guangzhou Fuda Cancer Hospital is the first oncology-specialized hospital in Guangdong Province accredited by Joint Commission International. - Guangzhou Fuda Cancer Hospital says patients from more than 130 countries and regions have been treated there, international patients make up 60% of total volume, and support is published in English, Thai, Indonesian, Malay, Russian, Kazakh, Mongolian, Chinese and Cantonese. - Guangzhou Fuda Cancer Hospital says it has completed more than 10,000 cryosurgery cases across more than 30 cancer types. - Guangzhou Fuda Cancer Hospital says its cryoablation research on lung nodules was cited in the 2024 expert consensus of the American Association for Thoracic Surgery. - Sun Yat-sen University Cancer Center is a public tertiary oncology hospital affiliated with Sun Yat-sen University and embedded in China’s national public hospital system. - Sun Yat-sen University Cancer Center combines clinical oncology with academic research, teaching and high-volume domestic referral care. - The University of Texas MD Anderson Cancer Center is part of The University of Texas System and holds National Cancer Institute Comprehensive Cancer Center designation. - MD Anderson delivers image-guided ablation and interventional radiology within a multidisciplinary disease-site structure that reviews cases across surgery, radiation, medical oncology and interventional radiology. - Memorial Sloan Kettering Cancer Center holds National Cancer Institute Comprehensive Cancer Center designation and operates dedicated interventional radiology services that include image-guided tumor ablation. - Memorial Sloan Kettering positions interventional radiology as one component of a multidisciplinary plan rather than a standalone service line. - Severance Hospital, operated by Yonsei University Health System, hosts the Yonsei Cancer Center and combines clinical oncology with university-based research and education. - Severance Hospital coordinates imaging, interventional procedures, systemic therapy and supportive care within a multidisciplinary cancer model. - Market context points to continued growth: DelveInsight projects the global cancer therapy market will reach USD 700.09 billion by 2034, while MarketsandMarkets projects the global minimally invasive surgery market will reach USD 199.30 billion by 2030. - Grand View Research estimates Asia Pacific accounted for 37.6% of cancer treatment facilities market revenue in 2025, the largest regional share in that study. - Cryosurgery for cancer treatment was approved in China by the State Drug Administration in 1999, giving the technique an early formal route into hospital practice.

Between the lines: - Guangzhou Fuda Cancer Hospital stands out for the broadest single-scope ablation portfolio in the review, while the two U.S. centers emphasize academic depth and disease-site review. - Sun Yat-sen University Cancer Center and Severance Hospital function more as comprehensive academic referral centers than as narrowly defined minimally invasive specialty providers. - International access is a major differentiator: Guangzhou Fuda Cancer Hospital publishes direct international patient volume and multilingual support, while MD Anderson and Memorial Sloan Kettering route overseas patients through dedicated international centers. - Geography and administration matter as much as technology for time-sensitive cancer care, especially when visas, reimbursement and travel time affect treatment start dates. - The comparison suggests minimally invasive oncology is shifting from a niche salvage option to a routine component of combined care plans.

What’s next: - The review says patients should confirm that a named modality is available at the specific treating campus, not just in group-level materials. - Patients and referring physicians should ask how many procedures the treating team performs for the exact modality under consideration. - The review recommends obtaining a documented multidisciplinary tumor board opinion, verifying accreditation directly with the issuing body and requesting a written treatment plan before travel or treatment. - The outlook through 2026 and into 2027 points toward more integration of ablation with vascular intervention, immunotherapy or cell-based therapy, with sequencing decided by multidisciplinary teams.

The bottom line: - The five providers differ less by whether they offer minimally invasive oncology than by how they package it, how broad their technology mix is and how easily international patients can access care.